45 research outputs found
SΓΆr WilliamβΔ±n muaΕakasΔ±
Alexandre Dumas'nΔ±n HanΔ±mlara Mahsus Gazete'de yayΔ±mlanan SΓΆr WilliamβΔ±n MuaΕakasΔ± adlΔ± romanΔ±nΔ±n ilk ve son tefrikalar
ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΠΊΠ°ΡΠ°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄Π΅ΠΏΠ°ΡΠ°ΡΠΈΠ½ΠΈΠ·Π°ΡΠΈΠΈ Π΄ΠΈΠ·Π΅Π»ΡΠ½ΡΡ ΡΠΎΠΏΠ»ΠΈΠ²
ΠΠ±ΡΠ΅ΠΊΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΏΡΠΎΡΠ΅ΡΡ ΠΊΠ°ΡΠ°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄Π΅ΠΏΠ°ΡΠ°ΡΠΈΠ½ΠΈΠ·Π°ΡΠΈΠΈ Π΄ΠΈΠ·Π΅Π»ΡΠ½ΡΡ
ΡΠΎΠΏΠ»ΠΈΠ².
Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ Π·Π°ΠΊΠ»ΡΡΠ°Π΅ΡΡΡ Π² ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ°Π±ΠΎΡΡ ΡΡΡΠ°Π½ΠΎΠ²ΠΊΠΈ ΠΊΠ°ΡΠ°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠ΄ΡΠΎΠ΄Π΅ΠΏΠ°ΡΠ°ΡΠΈΠ½ΠΈΠ·Π°ΡΠΈΠΈ Π΄ΠΈΠ·Π΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠΏΠ»ΠΈΠ²Π° ΠΏΡΡΠ΅ΠΌ ΠΏΠΎΠ΄Π±ΠΎΡΠ° ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ΅ΠΆΠΈΠΌΠΎΠ² Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ. Π ΠΏΡΠΎΡΠ΅ΡΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»Π° ΡΠΎΠ·Π΄Π°Π½Π° ΠΌΠΎΠ΄Π΅Π»Ρ ΡΠ΅Π°ΠΊΡΠΎΡΠ° Π΄Π΅ΠΏΠ°ΡΠ°ΡΠΈΠ½ΠΈΠ·Π°ΡΠΈΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠΈΡΡΠ΅ΠΌΡ HYSYS, ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΎΡΠ΅Π½ΠΊΠ° Π²Π»ΠΈΡΠ½ΠΈΡ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² Π½Π° ΠΏΡΠΎΡΠ΅ΡΡ ΠΊΠ°ΡΠ°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄Π΅ΠΏΠ°ΡΠ°ΡΠΈΠ½ΠΈΠ·Π°ΡΠΈΠΈ. ΠΠΎΠ΄ΠΎΠ±ΡΠ°Π½Ρ ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΡΠ΅ ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡΡ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π΄Π΅ΠΏΠ°ΡΠ°ΡΠΈΠ½ΠΈΠ·Π°ΡΠΈΠΈ Π΄Π»Ρ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° Π΄ΠΈΠ·Π΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠΏΠ»ΠΈΠ²Π° Π·ΠΈΠΌΠ½Π΅Π³ΠΎ ΠΈ Π°ΡΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΠΎΡΡΠ°Π²Π° ΡΡΡΡΡ.The object of research is the process of catalytic dewaxing of diesel fuels. The purpose of the work is to increase the efficiency of the catalytic hydrodewaxing of diesel fuel by selecting the optimal technological regimes using the mathematical modeling method. During the research, a model of a dewaxing reactor was developed using the HYSYS system, an assessment of the effect of process parameters on the catalytic dewaxing process was carried out. Optimum temperatures of the process of dewaxing for the production of winter and Arctic diesel oil, depending on the composition of the raw materials, were selected
Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study
BACKGROUND: The aim of the study was to determine the maximal tolerated dose (MTD) of gemcitabine every two weeks concurrent to radiotherapy, administered during an aggressive program of sequential and simultaneous radiochemotherapy for locally advanced, unresectable non-small cell lung cancer (NSCLC) and to evaluate the efficacy of this regime in a phase II study. METHODS: 33 patients with histologically confirmed NSCLC were enrolled in a combined radiochemotherapy protocol. 29 patients were assessable for evaluation of toxicity and tumor response. Treatment included two cycles of induction chemotherapy with gemcitabine (1200 mg/m(2)) and vinorelbine (30 mg/m(2)) at day 1, 8 and 22, 29 followed by concurrent radiotherapy (2.0 Gy/d; total dose 66.0 Gy) and chemotherapy with gemcitabine every two weeks at day 43, 57 and 71. Radiotherapy planning included [(18)F] fluorodeoxyglucose positron emission tomography (FDG PET) based target volume definition. 10 patients were included in the phase I study with an initial gemcitabine dose of 300 mg/m(2). The dose of gemcitabine was increased in steps of 100 mg/m(2 )until the MTD was realized. RESULTS: MTD was defined for the patient group receiving gemcitabine 500 mg/m(2 )due to grade 2 (next to grade 3) esophagitis in all patients resulting in a mean body weight loss of 5 kg (SD = 1.4 kg), representing 8% of the initial weight. These patients showed persisting dysphagia 3 to 4 weeks after completing radiotherapy. In accordance with expected complications as esophagitis, dysphagia and odynophagia, we defined the MTD at this dose level, although no dose limiting toxicity (DLT) grade 3 was reached. In the phase I/II median follow-up was 15.7 months (4.1 to 42.6 months). The overall response rate after completion of therapy was 64%. The median overall survival was 19.9 (95% CI: [10.1; 29.7]) months for all eligible patients. The median disease-free survival for all patients was 8.7 (95% CI: [2.7; 14.6]) months. CONCLUSION: After induction chemotherapy, the maximum tolerated dose and frequency of gemcitabine was defined at 500 mg/m(2 )every two weeks in three cycles during a maximum of 7 weeks of thoracic radiotherapy for the phase II study. This regimen represents an effective and tolerable therapy in the treatment of NSCLC
ΠΠ²ΡΠΎΠΌΠ°ΡΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ° ΡΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ Π±ΠΈΠ·Π½Π΅Ρ-ΠΏΡΠΎΡΠ΅ΡΡΠ°ΠΌΠΈ Π½Π° Π±Π°Π·Π΅ ΠΌΠ°Π»ΠΎΠ³ΠΎ ΠΏΡΠ΅Π΄ΠΏΡΠΈΡΡΠΈΡ
ΠΡΠΎΠ΅ΠΊΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΈΡΡΠ΅ΠΌΡ Π°Π²ΡΠΎΠΌΠ°ΡΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ Π±ΠΈΠ·Π½Π΅Ρ-ΠΏΡΠΎΡΠ΅ΡΡΠ°ΠΌΠΈ Π½Π° Π±Π°Π·Π΅ ΠΌΠ°Π»ΠΎΠ³ΠΎ ΠΏΡΠ΅Π΄ΠΏΡΠΈΡΡΠΈΡ ΠΏΠΎ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Ρ ΠΏΠ»Π°ΡΡΠΈΠΊΠ° Π΄Π»Ρ 3D-ΠΏΠ΅ΡΠ°ΡΠΈ. ΠΠ±ΡΠ΅ΠΊΡΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²Π»ΡΠ΅ΡΡΡ Π±ΠΈΠ·Π½Π΅Ρ-ΠΏΡΠΎΡΠ΅ΡΡΡ, ΠΏΡΠΎΡΠ΅ΠΊΠ°ΡΡΠΈΠ΅ Π½Π° ΠΏΡΠ΅Π΄ΠΏΡΠΈΡΡΠΈΠΈ ΠΏΠΎ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Ρ ΠΏΠ»Π°ΡΡΠΈΠΊΠ° Π΄Π»Ρ 3D-ΠΏΠ΅ΡΠ°ΡΠΈ
Π¦Π΅Π»ΡΡ ΡΠ°Π±ΠΎΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΡΠΈΡΡΠ΅ΠΌΡ ΡΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ Π±ΠΈΠ·Π½Π΅Ρ-ΠΏΡΠΎΡΠ΅ΡΡΠ°ΠΌΠΈ.Designing an automated business process management system based on a small plastic manufacturing enterprise for 3D printin